Cynata reports Phase I data for mesenchymal stem cell GvHD product

Cynata Therapeutics Ltd. (ASX:CYP) reported data from eight evaluable patients with steroid-resistant grade II-IV acute graft-versus-host disease (GvHD) in the first cohort of the Phase I CYP-GvHD-P1-01 trial

Read the full 287 word article

User Sign In